Prescribing pattern of drugs in chronic kidney disease patients undergoing maintenance hemodialysis in a tertiary care hospital, Assam
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20253730Keywords:
CKD, Hemodialysis, Prescribing pattern, Drug utilizationAbstract
Background: Chronic kidney disease (CKD) is a progressive disorder associated with significant morbidity and mortality. Patients undergoing maintenance hemodialysis require multiple medications for comorbid conditions, prevention of complications, and improvement of quality of life. Assessing prescribing patterns helps in evaluating rationality of drug use and identifying areas for optimization. Purpose of the study was to evaluate the prescribing pattern of drugs in CKD patients undergoing maintenance hemodialysis in a tertiary care hospital in Assam.
Methods: The study was a cross-sectional observational study carried out in the department of pharmacology and medicine. The prescriptions of CKD patients under maintenance haemodialysis were gathered and examined in terms of demographic profile, comorbidities, classes of drugs prescribed, and mean number of drugs per prescription. Data were analysed and prescribing indicators were assessed according to WHO core indicators.
Results: The 120 prescriptions were examined. The average age of the patients was 55.6, and the majority of them were men. The most common comorbidities were hypertension and diabetes mellitus. Polypharmacy was observed with an average of 10.5 drugs per prescription. The most frequently prescribed classes of drugs were antihypertensives (calcium channel blockers, betablockers, diuretics), phosphate binders, erythropoiesis-stimulating agents, diuretics, and nutritional supplements. The rate of generic prescribing was 78.16 and rate of essential drug list adherence was 76.26.
Conclusions: Polypharmacy is common among CKD patients on maintenance hemodialysis. Rational drug use and adherence to WHO and evidence-based guidelines is essential to improve disease outcomes and reduce treatment burden.
Metrics
References
Jha V, Wang AY, Wang H. The impact of CKD identification in large countries: The burden of illness. Nephrol Dial Transplant. 2012;27(3):iii32-8. DOI: https://doi.org/10.1093/ndt/gfs113
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52. DOI: https://doi.org/10.1016/S0140-6736(16)32064-5
Jha V. Current status of end-stage renal disease care in India and strategies for its improvement. Kidney Int Suppl. 2010;77(1):S50-4.
Berns JS. Drug prescribing in patients with chronic kidney disease. Am Fam Physician. 2010;82(10):1131-8.
Ahlawat R, Cruz SD, Tiwari P. Drug utilization pattern in chronic kidney disease patients at a tertiary care public teaching hospital: Evidence from a cross sectional study. J Pharma Care Health Sys. 2015;3(1):149. DOI: https://doi.org/10.4172/2376-0419.1000149
World Health Organization. Promoting Rational Use of Medicines: Core Components—WHO Policy Perspectives on Medicines. 2002. Available at: http://apps.who.int/medicinedocs/en/d/Jh3011e/2.html. Accessed on 4 July 2025.
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease-a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. DOI: https://doi.org/10.1371/journal.pone.0158765
Bajait CS, Pimpalkhute S, Sontakke S, Jaiswal K, Dawri A. Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders. Indian J Pharmacol. 2014;46(1):35. DOI: https://doi.org/10.4103/0253-7613.125163
Santra S, Agrawal D, Kumar S, Mishra SS. A Study on the Drug Utilization Pattern in Patients with Chronic Kidney Disease with Emphasis on Antibiotics. J Integrative Nephrol Androl. 2015;2(3):85-9. DOI: https://doi.org/10.4103/2225-1243.161435
Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Kidney Int. 2003;64(2):610-5. DOI: https://doi.org/10.1046/j.1523-1755.2003.00109.x
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. DOI: https://doi.org/10.1186/s12877-017-0621-2
Papotti B, Marchi C, Adorni MP, Potì F. Drug-drug interactions in polypharmacy patients: the impact of renal impairment. Curr Res Pharmacol Drug Discov. 2021;29(2):100020. DOI: https://doi.org/10.1016/j.crphar.2021.100020
World Health Organization. WHO_EDM_2002.3.pdf. Available at: https://share.google/NZvYHePENaNHido0h. Accessed on 12 September 2025.
Devi D, George J. Diabetic nephropathy: Prescription trends in tertiary care. Indian J Pharm Sci. 2008;70(3):374. DOI: https://doi.org/10.4103/0250-474X.43007
Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20(6):1110-5. DOI: https://doi.org/10.1093/ndt/gfh771
Downloads
Published
How to Cite
Issue
Section
